Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $61.60 Average Price Target from Analysts

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has received an average recommendation of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $61.60.

Several equities analysts have recently issued reports on SUPN shares. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $40.00 to $65.00 in a research report on Thursday, October 9th. Cantor Fitzgerald upped their price target on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research report on Tuesday, September 30th. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Stifel Nicolaus lifted their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th.

Supernus Pharmaceuticals Trading Up 0.2%

Supernus Pharmaceuticals stock opened at $51.45 on Friday. The stock has a 50-day moving average price of $47.73 and a two-hundred day moving average price of $44.72. Supernus Pharmaceuticals has a 12 month low of $29.16 and a 12 month high of $57.65. The company has a market capitalization of $2.95 billion, a PE ratio of -151.32, a P/E/G ratio of 0.50 and a beta of 0.67.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36). The firm had revenue of $170.00 million for the quarter, compared to the consensus estimate of $175.82 million. Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.The business’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.69 earnings per share. As a group, analysts predict that Supernus Pharmaceuticals will post 2.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Frank Mottola sold 20,000 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $50.41, for a total value of $1,008,200.00. Following the sale, the senior vice president directly owned 15,496 shares of the company’s stock, valued at approximately $781,153.36. This represents a 56.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 710 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the transaction, the vice president owned 14,508 shares in the company, valued at approximately $644,735.52. The trade was a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. 8.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Hantz Financial Services Inc. grew its stake in Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 281 shares during the period. USA Financial Formulas bought a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth approximately $50,000. EverSource Wealth Advisors LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $51,000. Smartleaf Asset Management LLC increased its stake in shares of Supernus Pharmaceuticals by 30.8% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 268 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at $55,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.